by Maria Zannes | Jan 13, 2025 | Press Releases
SAN ANTONIO, TX (Jan. 13, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported the results of the Company’s CyPath® Lung...
by Maria Zannes | Dec 17, 2024 | Press Releases
SAN ANTONIO, TX (Dec. 17, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, invites investors to a webinar on Dec. 19, 2024, at 4:15 p.m. ET. The...
by Maria Zannes | Dec 12, 2024 | Press Releases
Noninvasive CyPath® Lung test for lung cancer contributes to growing revenues SAN ANTONIO, TX (Dec. 12, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage...
by Maria Zannes | Dec 5, 2024 | Press Releases
SAN ANTONIO, TX (Dec. 5, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, will join Federal Supply System (FSS) officials today in a joint...
by Maria Zannes | Nov 14, 2024 | Press Releases
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 Expanded CyPath® Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states Number of physician offices signed increased 75% over Q2 2024...
